UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.
UroGen Pharma (URGN) announced that the Centers for Medicare and Medicaid Services, CMS, has assigned a permanent Healthcare Common Procedure ...
PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...
On Monday, GE HealthCare announced new partnerships with The Queens Health System in Hawaii and Duke Health in North Carolina to develop AI-powered operations software. The health systems will ...
The new qualification, known as V-Levels, will support young people into either jobs or study and streamline around 900 existing qualifications available alongside A and T-Levels, the government has ...
Abstract: Although the semantic communication with joint semantic-channel coding design has shown promising performance in transmitting data of different modalities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback